ASLAN Pharmaceuticals Limited
ASLAN Pharmaceuticals Limited (ASLN) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
asln · stock forecast · 4 analysts (3M) · FMP · updated Apr 25, 2025
Analyst Rating & Consensus
Based on 4 Wall Street analysts in the past 3 months
Buy
4 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.60
Short-Term Price Prediction
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ASLN · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-05-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-04-23 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-04-15 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-03-18 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-03-13 | Piper Sandler | Maintains | Overweight→Overweight |
| 2024-03-11 | Piper Sandler | Maintains | Overweight→Overweight |
| 2023-11-06 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-08-14 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-08-14 | Roth MKM | Maintains | Buy→Buy |
| 2023-08-13 | Roth MKM | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on ASLAN Pharmaceuticals Limited (ASLN) stock. Of the recent 26 rating actions, 0 were upgrades and 0 were downgrades. 4 analysts currently cover ASLN.
Analyst Recommendation Trends
ASLN analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$12M
↑ 77.8% YoY
Revenue Next Year
$9M
↓ 25.0% YoY
EPS This Year
$-16.09
EPS Next Year
$-0.56
↓ 96.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast ASLN EPS of $-16.09 for the current fiscal year, based on estimates from 1 analysts. The ASLN revenue forecast is $12M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ASLN stock forecast is supported by two independent data sources: analyst consensus ratings from 4 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ASLN price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
ASLAN Pharmaceuticals Limited trades on NASDAQ under the ticker ASLN. The ASLN stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
ASLN forecast · 8 questionsAccording to 4 Wall Street analysts, the average 12-month ASLN price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.60.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.